GSA Capital Partners’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

GSA Capital Partners’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,559	Closed	-$1.27M	–	1895
2021 Q3	$1.27M	Buy	17,559 +251	+1%	+$19.2K	0.13%	195
2021 Q2	$1.66M	Buy	17,308 +14,250	+466%	+$1.57M	0.19%	96
2021 Q1	$452K	Sell	3,058 -3,011	-50%	-$546K	0.08%	409
2020 Q4	$849K	Buy	6,069 +1,240	+26%	+$201K	0.14%	179
2020 Q3	$733K	Buy	+4,829	New	+$788K	0.12%	210
2016 Q3	–	Sell	-132	Closed	-$144K	–	2020
2016 Q2	$144K	Buy	+132	New	+$166K	0.01%	1636

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's NBSE Position: Q4 2021 in Review

GSA Capital Partners sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2021, closing a stake of 17,559 shares — an estimated $1.27M sold.

GSA Capital Partners first reported a position in NBSE in Q2 2016 and held it in 6 quarters. The position peaked at $1.66M in Q2 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q4 2021.

GSA Capital Partners reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
GSA Capital Partners sold 17,559 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.27M.
GSA Capital Partners first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2016 and held it in 6 quarters.
GSA Capital Partners's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.66M in Q2 2021.
45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.